Breakthrough’ breast cancer drugs approved

Two new ‘breakthrough’ breast cancer drugs have been approved, giving new hope to women with previously untreatable breast cancer.

The National Institute for Health and Care Excellence (NICE) has given the go-ahead for palbociclib and ribociclib to be used on the NHS in England.

Palbociclib had previously been refused because its cost was judged to be too high in comparison to its effectiveness.

The drugs have been shown to slow down advanced cancer for at least 10 months, delaying the need for chemotherapy. Read more… 

Join Our Mailing List